THERAPY DOSSIER · th-89a7b42a5793

BP-C2 (lignin-derived polyphenolic composition with ammonium molybdate)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03627390 ↗PHASE2completed

Effect of BP-C1 in treatment of inoperable pancreatic cancer patients (BP-C2 comparator)

Metastatic Pancreatic Cancer · Unresectable Pancreatic Cancer

Enrolment: 16 · Results not recorded

NCT04186585 ↗PHASE1recruiting

Recommended dose estimation of BP-C2 in patients with prostate cancer: phase I dose-finding study

Prostate Cancer

Enrolment: 8 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29251085 ↗2017Reported benefit

Radioprotective and radiomitigative effects of BP-C2, a novel lignin-derived polyphenolic composition with ammonium molybdate, in two mouse strains exposed to total body irradiation.

MouseRadiationCBA and C57BL/6Male81.0 mg/kgStarting 24 hours after total body irradiation

Model: Total body irradiation, 4.0 to 8.0 Gy

BP-C2 improved 30-day survival (dose reduction factor 1.1) and increased endogenous spleen colony-forming units. After 5.0 Gy, colony-forming units were 6.7 +/- 5.1 with BP-C2 versus 2.3 +/- 2.3 with placebo (p = 0.0245) and surviving intestinal crypts were 133.7 +/- 13.9 versus 124.2 +/- 10.5 (p <…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…